SCHEMBL343573

SCHEMBL343573

CC(C)(C)OC[C@H]1NCCNC1=O

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
USP2 O75604 1/20 0.40
LMNA P02545 2/20 0.39
TSHR P16473 2/20 0.38
GLA P06280 1/20 0.38
KDM4E B2RXH2 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 3/20 0.35
GHSR Q92847 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26724613 1.00 SMN1; SMN2 (0.40) SMN1; SMN2USP2LMNATSHRGLA
SCHEMBL345484 1.00 SMN1; SMN2 (0.40) SMN1; SMN2USP2LMNATSHRGLA
Acetic Acid SCHEMBL2774932 0.94 GLA (0.44) SMN1; SMN2USP2LMNATSHRGLA
SCHEMBL27794175 0.80 GLA (0.53) SMN1; SMN2USP2LMNATSHRGLA
SCHEMBL27794179 0.80 GLA (0.53) SMN1; SMN2USP2LMNATSHRGLA
SCHEMBL28637073 0.79 LMNA (0.44) SMN1; SMN2USP2LMNATSHRGLA
SCHEMBL1385739 0.79 LMNA (0.44) SMN1; SMN2USP2LMNATSHRGLA
SCHEMBL1385740 0.79 LMNA (0.44) SMN1; SMN2USP2LMNATSHRGLA
SCHEMBL344602 0.78 SMN1; SMN2 (0.46) SMN1; SMN2USP2LMNATSHRGLA
SCHEMBL26724598 0.74 LMNA (0.41) SMN1; SMN2USP2LMNATSHRGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109928971-B Aryl substituted aminotetrahydropyrans and uses thereof 广东东阳光药业股份有限公司 2024-01-16 CN disclosed
WO-2023214011-A1 ENZYMATIC METHOD FOR PREPARING (R)-3-AMINO-4-ARYL-BUTANOIC ACID DERIVATIVES ENZYMICALS AG (DE) 2023-11-09 WO disclosed
EP-4273254-A1 ENZYMATIC METHOD FOR PREPARING (R)-3-AMINO-4-ARYL-BUTANOIC ACID DERIVATIVES Enzymicals AG (DE) 2023-11-08 EP disclosed
US-20180086765-A1 NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME KYUNG DONG PHARM. CO., LTD. (KR) 2018-03-29 US disclosed
US-20180086765-A1 NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME KYUNG DONG PHARM. CO., LTD. (KR) 2018-03-29 US disclosed
US-20180086765-A1 NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME KYUNG DONG PHARM. CO., LTD. (KR) 2018-03-29 US disclosed
EP-3262025-A1 NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME Kyung Dong Pharm. Co., Ltd. (KR) 2018-01-03 EP disclosed
EP-2351567-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETES OR OBESITY COMPRISING A COMPOUND THAT INHIBITS ACTIVITY OF DIPEPTIDYL PEPTIDASE-IV, AND OTHER ANTIDIABETIC OR ANTIOBESITY AGENTS AS ACTIVE INGREDIENTS DONG A ST CO LTD (KR) 2017-11-22 EP disclosed
WO-2016204376-A1 NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME KYUNG DONG PHARM. CO., LTD. (KR) 2016-12-22 WO disclosed
WO-2016204376-A1 NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME KYUNG DONG PHARM. CO., LTD. (KR) 2016-12-22 WO disclosed
US-20120016126-A1 METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DONG-A PHARMACEUTICAL. CO., LTD (KR) 2012-01-19 US disclosed
US-20120016125-A1 METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DONG-A PHARMACEUTICAL. CO., LTD (KR) 2012-01-19 US disclosed
US-8030315-B2 DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity DONG-A PHARM. CO., LTD. (KR) 2011-10-04 US disclosed
US-20110201624-A1 Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and other Antidiabetic or Antiobesity Agents as Active Ingredients DONG-A PHARMACEUTICAL. CO., LTD (KR) 2011-08-18 US disclosed
EP-2351567-A2 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETES OR OBESITY COMPRISING A COMPOUND THAT INHIBITS ACTIVITY OF DIPEPTIDYL PEPTIDASE-IV, AND OTHER ANTIDIABETIC OR ANTIOBESITY AGENTS AS ACTIVE INGREDIENTS Dong-A Pharmaceutical Co., Ltd. (KR) 2011-08-03 EP disclosed
WO-2010114291-A2 IMPROVED METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE 동아제약 주식회사 (KR) 2010-10-07 WO disclosed
WO-2010114292-A2 IMPROVED METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE 동아제약 주식회사 (KR) 2010-10-07 WO disclosed
US-20100120790-A1 DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY DONG-A PHARM. CO., LTD (KR) 2010-05-13 US disclosed
EP-2142519-A1 DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY Dong-A Pharm.Co., Ltd. (KR) 2010-01-13 EP disclosed
WO-2008130151-A1 DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY DONG-A PHARM. CO., LTD. (KR) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016126-A1 METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DPP4, DPP3, DPP7 SMN1; SMN2 2954/4885USP2 857/4885LMNA 3756/4885
US-20180086765-A1 NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME DPP4, DPP7, DPP9 SMN1; SMN2 4126/4885USP2 762/4885LMNA 3536/4885
US-20120016125-A1 METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DPP4, DPP3, DPP7 SMN1; SMN2 3968/4885USP2 875/4885LMNA 3276/4885
US-20100120790-A1 DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY DPP4, DPP7, DPP3 SMN1; SMN2 3576/4885USP2 2583/4885LMNA 3331/4885
US-20110201624-A1 Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and other Antidiabetic or Antiobesity Agents as Active Ingredients DPP4, DPP3, DPP7 SMN1; SMN2 4345/4885USP2 2666/4885LMNA 3173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.